HONG KONG – In a move that could lead to more and easier access to better medicines at the local level, China plans to eliminate fixed prices for drugs next month. And, despite public concerns, the regulator said drug prices will not shoot up even after price caps are taken away. Read More

SHANGHAI – Each year investors looking to ride the next big wave of opportunity convene at China's Healthcare Investment Conference to test the waters. This year, the promise of technology to tackle some of China's most complicated health care woes, summed up by the term e-Health, generated the most buzz. Read More

HONG KONG – With a third round of funding in hand, Taiwanese contract manufacturer and biosimilars maker JHL Biotech Inc. is that much closer to its first filing in Europe and an IPO later this year. Read More

SAN FRANCISCO – With international dealmaking often a key element of the biopharma asset development adventure, the path to success in Japan took center stage during the first day of Allicense, an annual pilgrimage for the industry's top business development pros. Read More

HONG KONG – South Korean drugmaker Celltrion Inc. has received marketing approval for its star product, Remsima, an infliximab biosimilar, in Brazil and Venezuela, marking the beginning of the company's expansion into Latin America. Read More

HONG KONG – The discovery of a novel mechanism for blood pressure (BP) regulation in a study by researchers at the Riken Brain Science Institute (BSI) in Wako, Japan, could have important implications for the control of elevated BP and may lead to the discovery of new antihypertensive medications. Read More